Allergan, Inc. : AGN

All AGN Articles

189 Articles

Lee Jackson | Nov 17, 2015 at 10:35 AM EST

2 Great Tech Stocks Added to UBS Quality Growth Portfolio

The UBS Q-GARP portfolio has outperformed the S&P 500 by over 5% year to date, and there’s no reason to…

Chris Lange | Nov 3, 2015 at 11:45 AM EST

Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger

The health care sector may have sold off a fair amount since this past summer, but there is some M&A…

Chris Lange | Oct 31, 2015 at 10:10 AM EDT

6 BioPharma Movers That Cannot Be Ignored

Last week, a few biotech companies made absolutely massive runs, and some had serious falls.

Jon C. Ogg | Oct 29, 2015 at 11:05 AM EDT

What a Combined Allergan and Pfizer Might Actually Look Like

Allergan has issued a press release that confirms some of the rumors floating in the market that it has been…

Lee Jackson | Oct 28, 2015 at 10:35 AM EDT

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.

Trey Thoelcke | Oct 9, 2015 at 7:05 AM EDT

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably…

Lee Jackson | Oct 8, 2015 at 10:15 AM EDT

Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now

We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that…

Lee Jackson | Aug 11, 2015 at 10:35 AM EDT

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

A new research report from UBS makes an interesting switch in the Quality Growth At a Reasonable Price (Q-GARP) portfolio.

Chris Lange | Aug 5, 2015 at 2:05 PM EDT

What to Expect From Allergan Earnings

Allergan is scheduled to report its second-quarter financial results Thursday before the markets open.

Lee Jackson | Aug 4, 2015 at 9:35 AM EDT

UBS Makes August Changes to Equity Focus List Portfolio

In a new report, UBS made changes in the firm's Equity Focus list and updated other positions.

Lee Jackson | Aug 4, 2015 at 8:35 AM EDT

3 Potential Huge Takeover Targets in Biotech

In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech…

Jon C. Ogg | Jul 31, 2015 at 1:44 PM EDT

Teva Proves Its Decade-Hold Status With Massive Funding

ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday…

Chris Lange | Jun 17, 2015 at 10:45 AM EDT

What Allergan Is Looking to Add With Kythera

Allergan and Kythera Biopharmaceuticals announced that they have entered into a definitive agreement in which the former will acquire he…

Chris Lange | Mar 17, 2015 at 9:40 AM EDT

American Airlines Replaces Allergan in S&P 500

American Airlines will be the newest addition to the S&P 500, taking the place of Allergan.

Chris Lange | Mar 16, 2015 at 9:10 AM EDT

As Valeant Ups Salix Buyout, Will Endo Come Back?

Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based…

1 … 5 6 7 8 9 … 13

Allergan, Inc. : AGN

All AGN Articles

2 Great Tech Stocks Added to UBS Quality Growth Portfolio

Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger

6 BioPharma Movers That Cannot Be Ignored

What a Combined Allergan and Pfizer Might Actually Look Like

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

What to Expect From Allergan Earnings

UBS Makes August Changes to Equity Focus List Portfolio

3 Potential Huge Takeover Targets in Biotech

Teva Proves Its Decade-Hold Status With Massive Funding

What Allergan Is Looking to Add With Kythera

American Airlines Replaces Allergan in S&P 500

As Valeant Ups Salix Buyout, Will Endo Come Back?

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Allergan, Inc. : AGN

All AGN Articles

2 Great Tech Stocks Added to UBS Quality Growth Portfolio

Why 2 Analysts Are Talking Up a Pfizer-Allergan Merger

6 BioPharma Movers That Cannot Be Ignored

What a Combined Allergan and Pfizer Might Actually Look Like

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

What to Expect From Allergan Earnings

UBS Makes August Changes to Equity Focus List Portfolio

3 Potential Huge Takeover Targets in Biotech

Teva Proves Its Decade-Hold Status With Massive Funding

What Allergan Is Looking to Add With Kythera

American Airlines Replaces Allergan in S&P 500

As Valeant Ups Salix Buyout, Will Endo Come Back?

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%